Overexpression of antisense long non‑coding RNA ZNF710‑AS1‑202 promotes cell proliferation and inhibits apoptosis of clear cell renal cell carcinoma via regulation of ZNF710 expression

Li, Gang; Xie, Menghan; Huang, Zhenlin; Li, Hao; Li, Peng; Zhang, Zhengguo; Ding, Yinghui; Jia, Zhang; Yang, Jinjian

doi:10.3892/mmr.2020.11032

Cited by 5 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, Li and colleagues found that ZNF710-AS1-202 played a role in enhancing cell growth and suppressing cell death in clear cell renal cell carcinoma through the reverse regulation of ZNF710[ 30 ]. Nevertheless, there is no existing report on the regulatory impact of ZNF710-AS1-201 on tumors.…”

Section: Discussionmentioning

confidence: 99%

Immune-related long noncoding RNA zinc finger protein 710-AS1-201 promotes the metastasis and invasion of gastric cancer cells

Ding,

Chen,

Wang

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

BACKGROUND Gastric cancer (GC) is a prevalent malignant tumor of the gastrointestinal system. ZNF710 is a transcription factor (TF), and zinc finger protein 710 (ZNF710)-AS1-201 is an immune-related long noncoding RNA (lncRNA) that is upregulated in GC cells. AIM To assess the correlation between ZNF710-AS1-201 and immune microenvironment features and to investigate the roles of ZNF710-AS1-201 in the invasion and metastasis processes of GC cells. METHODS We obtained data from The Cancer Genome Atlas and Wujin Hospital. We assessed cell growth, migration, invasion, and programmed cell death using cell counting kit-8, EdU, scratch, Transwell, and flow cytometry assays. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to identify the potential downstream targets of ZNF710-AS1-201. RESULTS In GC tissues with low ZNF710-AS1-201 expression, immunoassays detected significant infiltration of various antitumor immune cells, such as memory CD8 T cells and activated CD4 T cells. In the low-expression group, the half-maximal inhibitory concentrations (IC50s) of 5-fluorouracil, cisplatin, gemcitabine, and trametinib were lower, whereas the IC50s of dasatinib and vorinostat were higher. The malignant degree of GC was higher and the stage was later in the high-expression group. Additionally, patients with high expression of ZNF710-AS1-201 had lower overall survival and disease-free survival rates. In vitro, the overexpression of ZNF710-AS1-201 greatly enhanced growth, metastasis, and infiltration while suppressing cell death in HGC-27 cells. In contrast, the reduced expression of ZNF710-AS1-201 greatly hindered cell growth, enhanced apoptosis, and suppressed the metastasis and invasion of MKN-45 cells. The expression changes in ZNF710 were significant, but the corresponding changes in isocitrate dehydrogenase-2, Semaphorin 4B, ARHGAP10, RGMB, hsa-miR-93-5p, and ZNF710-AS1-202 were not consistent or statistically significant after overexpression or knockdown of ZNF710-AS1-201, as determined by qRT-PCR. CONCLUSION Immune-related lncRNA ZNF710-AS1-201 facilitates the metastasis and invasion of GC cells. It appears that ZNF710-AS1-201 and ZNF710 have potential as effective targets for therapeutic intervention in GC. Nevertheless, it is still necessary to determine the specific targets of the ZNF710 TF.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune-related long noncoding RNA zinc finger protein 710-AS1-201 promotes the metastasis and invasion of gastric cancer cells

Ding,

Chen,

Wang

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…RP11-617F23.1 was also known as ZNF710-AS1-201 according to Ensembl database. Only one report concerning ZNF710-AS1-201, which demonstrated that the overexpression of ZNF710-AS1-201 was correlated with poor prognosis for patients with clear cell renal cell carcinoma [ 35 ]. This conclusion was consistent with our verification result.…”

Section: Discussionmentioning

confidence: 99%

Construction of a Prognostic Immune-Related LncRNA Risk Model for Gastric Cancer

Ding

Sun

Tan

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common malignancies, and novel prognostic biomarkers for it are urgently required. This study is aimed at screening a group of immune-related lncRNAs (IRLs) in predicting the prognosis of GC patients. Genetic and clinical information from the 360 GC patients was included in this study. Eight IRLs in lncRNA-miRNA-mRNA network were screened out according to differential expression analysis. A novel risk score model with three IRLs (MIR4435-1HG, UCA1, and RP11-617F23.1) were identified, and patients were assigned to a high-risk group and a low-risk group. Patients in the low-risk group had a better prognosis. In addition, two nomograms were developed to predict the prognosis of GC. We evaluated the correlation between IRLs and the immune infiltration level of GC using TIMER. Furthermore, we verified that RP11-617F23.1 was significantly upregulated in human GC tissues compared with their adjacent tissues. And, patients with high RP11-617F23.1 expression in tumor tissues had poorer survival. In conclusion, we established a novel risk model based on IRLs for predicting the prognosis of GC. Meanwhile, a novel IRL, RP11-617F23.1, could serve as a predictor of prognosis for patients with GC.

show abstract

“…ZNF710-AS1-202: The ZNF710-AS1-202 is a newly-found lncRNA, which was first unveiled to be a tumor suppressor in RCC and was significantly declined in RCC tissues 93 For example, the serum gradually increased during hepatocarcinogenesis (GIHCG) was significantly increased in RCC patients and can distinguish RCC patients from healthy controls with an AUC of 0.920 in the testing set 95 . Similarly, another study indicated that serum C-X-C motif chemokine ligand 2 (CXCL2) level was markedly higher than that in healthy subjects.…”

Section: Linc01939mentioning

confidence: 99%

Long Non-Coding RNAs: A Double-Edged Sword in Renal Cell Carcinoma Carcinogenesis

Liu¹,

Zhao²

2022

International J. of Pharmacology

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a malignant tumor that results in high mortality and a huge economic burden worldwide. Owing to the paucity of therapy options, it still has a poor prognosis. Therefore, it is of great importance to find an effective strategy for the treatment of RCC. Long Non-Coding RNAs (lncRNAs) emerge as a pivotal regulator of diverse cancers in many biological processes, including proliferation metastasis, apoptosis and metabolism by tethering with DNA, RNA or protein. Recently, a strong body of investigations revealed that lncRNAs play a critical role in carcinogenesis and cancer progression. Hence, this review provides a synopsis of the molecular mechanisms and clinical implications of lncRNAs in the progression of RCC and found that lncRNAs have the potential to be used clinically in RCC in the future.

show abstract

Overexpression of antisense long non‑coding RNA ZNF710‑AS1‑202 promotes cell proliferation and inhibits apoptosis of clear cell renal cell carcinoma via regulation of ZNF710 expression

Cited by 5 publications

References 30 publications

Immune-related long noncoding RNA zinc finger protein 710-AS1-201 promotes the metastasis and invasion of gastric cancer cells

Immune-related long noncoding RNA zinc finger protein 710-AS1-201 promotes the metastasis and invasion of gastric cancer cells

Construction of a Prognostic Immune-Related LncRNA Risk Model for Gastric Cancer

Long Non-Coding RNAs: A Double-Edged Sword in Renal Cell Carcinoma Carcinogenesis

Contact Info

Product

Resources

About